Segall Bryant & Hamill LLC Lowers Holdings in Globus Medical, Inc. $GMED

Segall Bryant & Hamill LLC trimmed its position in Globus Medical, Inc. (NYSE:GMED) by 19.8% in the 1st quarter, Holdings Channel reports. The firm owned 253,885 shares of the medical device company’s stock after selling 62,626 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Globus Medical were worth $21,875,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Invesco Ltd. increased its holdings in shares of Globus Medical by 1,235.2% in the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock worth $339,322,000 after purchasing an additional 3,595,339 shares during the period. Bank of Montreal Can raised its position in shares of Globus Medical by 15,317.1% in the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after buying an additional 3,351,380 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Globus Medical by 1,303.9% during the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after buying an additional 1,908,795 shares during the period. Fuller & Thaler Asset Management Inc. bought a new stake in Globus Medical during the fourth quarter valued at $90,411,000. Finally, Norges Bank purchased a new position in Globus Medical during the fourth quarter worth about $89,922,000. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on GMED. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Monday, July 13th. Royal Bank Of Canada cut their price objective on Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Wells Fargo & Company decreased their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Needham & Company LLC raised their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $102.08.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $78.99 on Friday. The firm has a market capitalization of $10.72 billion, a PE ratio of 18.37, a price-to-earnings-growth ratio of 1.63 and a beta of 0.95. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The firm has a fifty day moving average of $79.53 and a 200 day moving average of $85.61.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. During the same quarter last year, the business posted $0.68 earnings per share. The company’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Insider Activity at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 18.38% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.